Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Teams With Vanderbilt In Neuroscience Pact

This article was originally published in The Pink Sheet Daily

Executive Summary

Vanderbilt University’s neuroscience research group reaches its latest agreement with a pharma, this one covering compounds that treat symptoms of Alzheimer’s disease and schizophrenia by modulating a receptor in new ways.

You may also be interested in...



Academic Drug-Discovery Units Team Up To Share Knowledge, Facilitate Partnering

Founded in 2012, the Academic Drug Discovery Consortium intends to serve as a clearinghouse for both academia and industry on research underway at U.S. and international drug research programs. It won’t undertake tech transfer work itself, but the ADDC hopes to make it easier for academics and biopharma to work together.

Pursuit Of R&D Efficiency Continues As Regulatory Options Expand In 2013 – Tufts CSDD

Cutting non-core procedures – such as those supporting exploratory endpoints – from study budgets could save the industry $6 billion a year in drug development costs, the Tufts Center for the Study of Drug Development suggests in its 2013 industry outlook report.

Deals Of The Week: AstraZeneca/Vanderbilt, Medicago, OcellO/Merus

High-level executive changes at AstraZeneca continue pondering of where the British pharma turns next for growth – will it look to large-scale M&A again?

Related Content

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS074753

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel